Advancements in Non-Dopaminergic Treatments for Schizophrenia: A
                    Systematic Review of Pipeline Developments

Yuki Komatsu; Moe Takehara; Xenia Hart; Yuna Takahashi; Satoko Hori; Fumihiko Ueno; Hiroyuki Uchida

doi:10.1055/a-2307-6484

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2024; 57(05): 221-231
DOI: 10.1055/a-2307-6484

Review

Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments

Yuki Komatsu^‡

¹Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan

²Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan

,

Moe Takehara^‡

³Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan

,

Xenia Hart^‡

¹Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan

⁴Department of Molecular Neuroimaging, Medical Faculty Mannheim, Central Institute of Mental Health, Heidelberg University, Mannheim, Germany

,

Yuna Takahashi

³Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan

,

Satoko Hori

³Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan

,

Fumihiko Ueno

¹Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan

⁵Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada

⁶Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

,

Hiroyuki Uchida

¹Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan

› Author Affiliations

Abstract

Introduction Conventional antipsychotic drugs that attenuate dopaminergic neural transmission are ineffective in approximately one-third of patients with schizophrenia. This necessitates the development of non-dopaminergic agents.

Methods A systematic search was conducted for completed phase II and III trials of compounds for schizophrenia treatment using the US Clinical Trials Registry and the EU Clinical Trials Register. Compounds demonstrating significant superiority over placebo in the primary outcome measure in the latest phase II and III trials were identified. Collateral information on the included compounds was gathered through manual searches in PubMed and press releases.

Results Sixteen compounds were identified; four compounds (ulotaront, xanomeline/trospium chloride, vabicaserin, and roluperidone) were investigated as monotherapy and the remaining 12 (pimavanserin, bitopertin, BI 425809, encenicline, tropisetron, pregnenolone, D-serine, estradiol, tolcapone, valacyclovir, cannabidiol, and rimonabant) were examined as add-on therapy. Compared to the placebo, ulotaront, xanomeline/trospium chloride, vabicaserin, bitopertin, estradiol, cannabidiol, rimonabant, and D-serine showed efficacy for positive symptoms; roluperidone and pimavanserin were effective for negative symptoms; and encenicline, tropisetron, pregnenolone, tolcapone, BI 425809, and valacyclovir improved cognitive function.

Discussion Compounds that function differently from existing antipsychotics may offer novel symptom-specific therapeutic strategies for patients with schizophrenia.

Keywords

antipsychotic. schizophrenia - pipeline - non-dopaminergic

Full Text

References

References
1 McGrath J, Saha S, Chant D. et al. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008; 30: 67-76
2 Zhu Y, Krause M, Huhn M. et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: A systematic review with pairwise and network meta-analyses. Lancet Psychiatry 2017; 4: 694-705
3 Ceraso A, Lin JJ, Schneider-Thoma J. et al. Maintenance treatment with antipsychotic drugs in schizophrenia: A Cochrane systematic review and meta-analysis. Schizophr Bull 2022; 48: 738-740
4 Suzuki T, Remington G, Mulsant BH. et al. Treatment resistant schizophrenia and response to antipsychotics: A review. Schizophr Res 2011; 133: 54-62
5 Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: Data from a systematic review and meta-analysis. Can J Psychiatry 2017; 62: 772-777
6 Uchida H, Takeuchi H, Graff-Guerrero A. et al. Dopamine D2 receptor occupancy and clinical effects: A systematic review and pooled analysis. J Clin Psychopharmacol 2011; 31: 497-502
7 Ray WA, Chung CP, Murray KT. et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-235
8 Sakurai H, Bies RR, Stroup ST. et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: Analysis of the CATIE data. Schizophr Bull 2013; 39: 564-574
9 Adrianzén C, Arango-Dávila C, Araujo DM. et al. Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: Post hoc analysis from a 3-year observational study. Hum Psychopharmacol 2010; 25: 439-447
10 Haddaway NR, Page MJ, Pritchard CC. et al. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Systematic Reviews 2022; 18: e1230
11 Koblan KS, Kent J, Hopkins SC. et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med 2020; 382: 1497-1506
12 Dedic N, Jones PG, Hopkins SC. et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharmacol Exp Ther 2019; 371: 1-14
13 Shannon HE, Bymaster FP, Calligaro DO. et al. Xanomeline: A novel muscarinic receptor agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther 1994; 269: 271-281
14 Brannan SK, Sawchak S, Miller AC. et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med 2021; 384: 717-726
15 Shen JH, Zhao Y, Rosenzweig-Lipson S. et al. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. J Psychiatr Res 2014; 53: 14-22
16 Dunlop J, Watts SW, Barrett JE. et al. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. J Pharmacol Exp Ther 2011; 337: 673-680
17 Davidson M, Saoud J, Staner C. et al. Efficacy and safety of MIN-101: A 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry 2017; 174: 1195-1202
18 Bugarski-Kirola D, Arango C, Fava M. et al. Pimavanserin for negative symptoms of schizophrenia: Results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry 2022; 9: 46-58
19 Vanover KE, Weiner DM, Makhay M. et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 2006; 317: 910-918
20 Alberati D, Moreau JL, Lengyel J. et al. Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 2012; 62: 1152-1161
21 Bugarski-Kirola D, Iwata N, Sameljak S. et al. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: Results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry 2016; 3: 1115-1128
22 Rosenbrock H, Desch M, Kleiner O. et al. Evaluation of pharmacokinetics and pharmacodynamics of BI 425809, a novel GlyT1 inhibitor: Translational studies. Clin Transl Sci 2018; 11: 616-623
23 Fleischhacker WW, Podhorna J, Groschl M. et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: A double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry 2021; 8: 191-201
24 Keefe RS, Meltzer HA, Dgetluck N. et al. Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology 2015; 40: 3053-3060
25 Prickaerts J, van Goethem NP, Chesworth R. et al. EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology 2012; 62: 1099-1110
26 Macor JE, Gurley D, Lanthorn T. et al. The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist. Bioorg Med Chem Lett 2001; 11: 319-321
27 Shiina A, Shirayama Y, Niitsu T. et al. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry 2010; 9: 27
28 Marx CE, Lee J, Subramaniam M. et al. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology (Berl) 2014; 231: 3647-3662
29 Kantrowitz JT, Epstein ML, Lee M. et al. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophr Res 2018; 191: 70-79
30 Kulkarni J, Gavrilidis E, Wang W. et al. Estradiol for treatment-resistant schizophrenia: A large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry 2015; 20: 695-702
31 Zürcher G, Colzi A, Da Prada M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm Suppl 1990; 32: 375-380
32 Prasad KM, Eack SM, Keshavan MS. et al. Antiherpes virus-specific treatment and cognition in schizophrenia: A test-of-concept randomized double-blind placebo-controlled trial. Schizophr Bull 2013; 39: 857-866
33 McGuire P, Robson P, Cubala WJ. et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am J Psychiatry 2018; 175: 225-231
34 Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel) 2019; 9
35 Kelly DL, Gorelick DA, Conley RR. et al. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: A randomized, double-blind, pilot study. J Clin Psychopharmacol 2011; 31: 86-91